S.8772 revises New York's insurance law to change how cost-sharing rules apply to high deductible health plans (HDHPs) sold with health savings accounts (HSAs). Across multiple statutory provisions (N.Y.
Ins. Law §§3216, 3221, 4303), the bill replaces language that deferred application of certain cost-sharing until an enrollee met the IRC §223 minimum deductible with language that allows coverage to be subject to the plan's annual deductible.
The bill also updates how third‑party prescription‑drug financial assistance is applied to deductibles and removes references to health reimbursement accounts in these contexts.
Why it matters: the statutory edits give New York insurers and plan sponsors more design flexibility but create a practical tension with federal HSA rules. By allowing plan deductibles to be applied even where doing so would make a consumer ineligible for HSA contributions under IRC §223, the law shifts the compliance burden onto carriers, sponsors, and consumers to ensure accurate HSA qualification and disclosure.
The act ties these changes to a January 1, 2027 effective date for affected policies and aligns timing with a related 2025 chapter amending the same subjects.
At a Glance
What It Does
The bill amends multiple sections of New York Insurance Law to permit insurers to apply a plan's annual deductible and other cost-sharing to HDHP coverage offered with HSAs even when that application would render a consumer ineligible for HSA contributions under 26 U.S.C. §223. It also revises how third‑party prescription‑drug payments and discounts must be counted toward cost‑sharing obligations and removes parallel references to health reimbursement accounts.
Who It Affects
Insurers that issue individual and group HDHPs in New York, employers that sponsor HDHPs with HSA options, HSA custodians and administrators, benefits brokers, and consumers who contribute to or rely on HSAs.
Why It Matters
The state change increases plan design latitude but raises federal‑state friction: federal tax law, not state law, determines HSA eligibility, so plans and sponsors must reconcile New York's permissive approach with IRC §223 to avoid misrepresenting HSA status to enrollees and custodians. The effective-date language also stages adoption for policies on or after Jan 1, 2027.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
S.8772 edits the Insurance Law in several parallel places to change how cost‑sharing works for HDHPs paired with health savings accounts. The prior statutory language essentially deferred applying certain cost‑sharing (notably deductibles) until a consumer met the minimum deductible required by federal IRC §223; the bill replaces that deferral with a simpler rule allowing coverage to be subject to the plan's annual deductible.
Practically, that means a plan may apply its normal deductible rules even if doing so would make an enrollee—and therefore contributions to their HSA—noncompliant with federal rules.
The bill repeats this change in three major title areas that govern individual policies, group policies, and contracts issued by nonprofit health entities, and it similarly revises parallel paragraphs that previously exempted certain required coverage from annual deductibles or coinsurance. It also amends the statutory treatment of third‑party prescription‑drug financial assistance (discounts, vouchers, manufacturer copay support): those amounts must continue to be credited against an insured's cost‑sharing, but the bill alters when and how that credit counts relative to the plan's deductible, and retains the statutory limitation to specified drug categories (e.g., brand‑name without AB‑rated generic, brand‑name with prior authorization, or covered generics).The act removes bracketed references to health reimbursement accounts in the HDHP/HSA provisions, narrowing the textual focus to HSAs.
Finally, the bill changes the effective‑date mechanics: it amends the earlier 2025 chapter's timing to make the operative date January 1, 2027 for policies and contracts issued, renewed, modified, altered, or amended on or after that date, while providing that the bill's own sections will take effect in the same manner and at the same time as the 2025 chapter. That creates a single date after which the new permissive deductible treatment and the revised prescription‑assistance counting rules apply to affected policies.
The Five Things You Need to Know
The bill amends N.Y. Ins. Law §§3216, 3221, and 4303 to allow HDHP coverage offered with an HSA to be subject to the plan's annual deductible even if doing so would cause HSA ineligibility under 26 U.S.C. §223.
It revises prescription‑drug provisions so third‑party payments and discounts are applied toward an enrollee's cost‑sharing in a way tied to the plan's deductible rather than the IRC §223 'minimum' deductible language used previously.
References to health reimbursement accounts are removed in the parallel HDHP/HSA provisions, narrowing the changes to HSAs.
The statutory drug‑assistance counting rules continue to apply only to specified drug categories (brand‑name without AB‑rated generic, brand‑name with AB‑rated generic accessed via prior authorization/appeal, or covered generics).
The operative effective date for affected policies is January 1, 2027; the act aligns its Sections 1–9 with the effective date and manner of the 2025 chapter that originally amended these topics.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Permits plan deductibles for HDHPs sold with HSAs
This provision replaces the prior deferment tied to the IRC §223 minimum deductible with language stating that coverage may be subject to the plan's annual deductible where applying cost‐sharing would render an enrollee HSA‑ineligible. For practitioners, the immediate mechanic is simple: the statute no longer compels insurers to wait until an enrollee has reached the federal minimum deductible before applying cost‑sharing; it permits normal plan deductible application. That shifts the downstream compliance question—whether the plan remains HSA‑qualified—into the operational domain of insurers, sponsors, and HSA custodians.
Narrows deductible exemptions for statutorily required coverage
This amendment keeps the structure that some mandated coverage need not be subject to annual deductibles or coinsurance, but it rewords the federal‑interaction clause so that if applying the requirement would cause HSA ineligibility under IRC §223, the requirement instead applies after the enrollee has satisfied the plan deductible (with the preventive‑care exception preserved). The practical implication: mandated benefits that insurers previously carved out from deductibles may now be re‑cast in a way that depends upon plan deductible mechanics rather than the IRC §223 minimum figure, requiring careful plan documentation and member notices.
Changes how third‑party prescription assistance counts toward cost‑sharing
The statutory rule that requires insurers to apply third‑party payments and discounts toward a consumer's deductible or out‑of‑pocket maximum remains, but the bill shifts the reference point to the plan deductible rather than the federal 'minimum' deductible language. The subsection retains its scope limitation—applying only to certain classes of drugs (brand‑name without AB generic, brand‑name with AB generic when accessed through prior authorization/appeal, or covered generics)—so the operational effect is targeted to drugs where patients commonly use manufacturer or other assistance.
Mirrors §3216 change for other policy categories
This subsection mirrors the change made in §3216(n) for the parallel statutory regime in §3221. It makes the same permissive statement that HDHP coverage offered with an HSA may be subject to the plan's annual deductible even if that application would trigger HSA ineligibility under IRC §223. The repetition across titles shows the legislature intended a uniform rule across individual, group, and other lines covered by these chapters.
Parallel edits for group/blanket policies and prescription‑drug assistance
These entries extend the same deductible and prescription‑assistance language to group and blanket policies: mandated coverage may apply after the plan deductible in situations that would otherwise affect HSA eligibility, and third‑party payments for drugs must be credited toward cost‑sharing with the same drug‑category limitations. Employers, TPAs, and brokers who administer group plans will need to adjust plan documents and member communications to reflect whether the plan remains HSA‑compatible under federal rules.
Applies edits to contracts issued by nonprofit health entities
These provisions insert the same deductible and drug‑assistance changes into the nonprofit carrier statute language so that hospital, medical expense indemnity, and health service contracts follow the new approach. The statute's drug‑category limits and prior‑authorization caveats remain in these subsections, preserving a targeted scope for the third‑party assistance rule even as the deductible language becomes permissive.
Establishes Jan. 1, 2027 operative date and syncs timing
Section 10 amends the earlier 2025 chapter to set the act's effective date at January 1, 2027 for policies and contracts issued, renewed, modified, altered, or amended on or after that date. Section 11 states that Sections 1–9 of this act will take effect on the same date and in the same manner as the 2025 chapter. For compliance teams, this creates a clear operational cutoff: carrier systems, SPD/summary plan material templates, and communications should be updated for plan actions effective on or after Jan. 1, 2027.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Insurers and plan designers — gain greater flexibility to apply plan deductibles and design cost‑sharing even where that may affect HSA qualification, enabling a wider array of product designs.
- Employers and plan sponsors — can structure employer‑sponsored HDHPs without being constrained by the prior statutory linkage to the IRC §223 minimum deductible, which may simplify benefit toggles for non‑HSA plan options.
- Consumers who prefer lower premiums and stricter cost‑sharing — may see plan designs that front‑load deductibles or rely more on traditional deductible structures, potentially lowering premium costs for some coverage tiers.
Who Bears the Cost
- HSA account holders — risk losing HSA contribution eligibility or tax advantages if plan cost‑sharing is applied in ways that conflict with IRC §223; they face potential tax and savings consequences.
- Benefits administrators, brokers, and HSA custodians — must reconcile plan design and federal HSA qualification, increase verification and disclosure work, and may face more member inquiries or disputes about account eligibility.
- State insurance regulators and carrier compliance teams — bear enforcement and supervisory burdens to ensure consumer notices are accurate and that carriers do not misrepresent HSA qualification; implementing new systems and templates will create upfront costs.
Key Issues
The Core Tension
The central dilemma is between state‑level flexibility for plan design and the federal tax rules that define HSA eligibility: the bill grants insurers and sponsors freedom to apply plan deductibles, but federal law ultimately governs whether consumers can contribute to HSAs—so the statute solves a state regulatory objective at the potential expense of consumer tax benefits and creates administrative and disclosure burdens to prevent harm.
The statute creates a state‑level permissive standard that cannot, by itself, change federal tax law. That yields a practical implementation knot: insurers may lawfully apply plan deductibles under state law, but doing so can render a plan non‑HSA‑qualified under IRC §223.
Carriers must therefore choose whether to: (a) maintain HSA‑qualified plan designs consistent with federal thresholds, (b) redesign products and label them as non‑HSA HDHPs, or (c) apply deductibles in ways that preserve HSA qualification while meeting state documentation and disclosure rules. Each path has operational and marketing consequences.
The bill's wording also introduces ambiguity. The shift from the phrase 'minimum deductible under 26 USC 223' to 'plan deductible' invites divergent interpretations: does 'plan deductible' mean the numeric deductible stated in the policy even if lower than IRC §223 requires, or the deductible as adjusted to meet federal HSA minimums?
That ambiguity raises compliance risk and could produce inconsistent consumer experiences. Additionally, removing health reimbursement account references narrows textual coverage but leaves open whether similar HRA‑linked designs will be treated differently in practice.
Finally, the effective‑date synchronization with the 2025 chapter reduces immediate disruption but requires careful coordination for renewals and plan amendments straddling the Jan. 1, 2027 cutoff.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.